TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune prof...

Full description

Saved in:
Bibliographic Details
Published inJournal of microbiology, immunology and infection Vol. 53; no. 3; pp. 368 - 370
Main Authors Wu, Dandan, Yang, Xuexian O.
Format Journal Article
LanguageEnglish
Published England Elsevier B.V 01.06.2020
Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC
Elsevier
Subjects
Betacoronavirus - immunology
Coronavirus Infections - drug therapy
Coronavirus Infections - pathology
COVID-19
Cytokine Release Syndrome - drug therapy
Cytokine storm
Cytokines - biosynthesis
Cytokines - immunology
Humans
JAK2 inhibitor
Janus Kinase 2 - antagonists & inhibitors
Pandemics
Pneumonia, Viral - drug therapy
Pneumonia, Viral - pathology
Pyrrolidines - pharmacology
SARS-CoV-2
Sulfonamides - pharmacology
TH17
Th17 Cells - immunology
COVID-19
SARS-CoV-2
JAK2 inhibitor
Cytokine storm
TH17
Online AccessGet full text

Cover

More Information
Summary:COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1684-1182
1995-9133
1995-9133
DOI:10.1016/j.jmii.2020.03.005